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Abstract
Background: Interest in phage therapy has grown over the past decade due to the rapid emergence of antibiotic
resistance in bacterial pathogens. However, the use of bacteriophages for therapeutic purposes has raised concerns
over the potential for immune response, rapid toxin release by the lytic action of phages, and difficulty in dose
determination in clinical situations. A phage that kills the target cell but is incapable of host cell lysis would
alleviate these concerns without compromising efficacy.
Results: We developed a recombinant lysis-deficient Staphylococcus aureus phage P954, in which the endolysin
gene was rendered nonfunctional by insertional inactivation. P954, a temperate phage, was lysogenized in S.
aureus strain RN4220. The native endolysin gene on the prophage was replaced with an endolysin gene disrupted
by the chloramphenicol acetyl transferase (cat) gene through homologous recombination using a plasmid
construct. Lysogens carrying the recombinant phage were detected by growth in presence of chloramphenicol.
Induction of the recombinant prophage did not result in host cell lysis, and the phage progeny were released by
cell lysis with glass beads. The recombinant phage retained the endolysin-deficient genotype and formed plaques
only when endolysin was supplemented. The host range of the recombinant phage was the same as that of the
parent phage. To test the in vivo efficacy of the recombinant endolysin-deficient phage, immunocompromised
mice were challenged with pathogenic S. aureus at a dose that results in 80% mortality (LD80). Treatment with the
endolysin-deficient phage rescued mice from the fatal S. aureus infection.
Conclusions: A recombinant endolysin-deficient staphylococcal phage has been developed that is lethal to
methicillin-resistant S. aureus without causing bacterial cell lysis. The phage was able to multiply in lytic mode
utilizing a heterologous endolysin expressed from a plasmid in the propagation host. The recombinant phage
effectively rescued mice from fatal S. aureus infection. To our knowledge this is the first report of a lysis-deficient
staphylococcal phage.
Background
Bacteriophages are attractive as therapeutic agents because
they are safe for humans and highly specific and lethal to
the bacteria they target. Further, phages can be developed
rapidly to combat the emergence of antibiotic-resistant
pathogenic bacteria [1,2]. Phage therapy is currently prac-
ticed routinely and successfully in countries such as
Poland and Russia [3]. The recent approval of commercial
phage preparations by the United States Food and Drug
Administration to prevent bacterial contamination of meat
and poultry [4] may pave the way for the global use of
phage therapy to control bacteria in human infections.
The development of phages for therapy has been ham-
pered by concerns over the potential for immune
response, rapid toxin release by the lytic action of phages,
and difficulty of dose determination in clinical situations
[5]. Phages multiply logarithmically in infected bacterial
cells, and the release of progeny phage occurs by lysis of
the infected cell at the end of the infection cycle, which
involves the holin-endolysin system [6,7]. Holins create a
lesion in the cytoplasmic membrane through which
endolysins gain access to the murein layer [7]. Endolysins
are peptidoglycan hydrolases that degrade the bacterial
cell wall, leading to cell lysis and release of progeny
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enon from a therapeutic perspective is the development
of immunogenic reactions due to large uncontrolled
amounts of phages in circulation [9]. Such concerns
must be addressed before phage therapy can be widely
accepted [5,10].
This work features engineered bacteriophages that are
incapable of lysing bacterial cells because they lack endoly-
sin enzymatic activity. We previously produced, as a
model, a recombinant lysis-deficient version of T4 bacter-
iophage that infects Escherichia coli [11,12]. Phages have
also been engineered to be non- replicating or to possess
additional desirable properties [13-15]. In an experimental
E. coli infection model, the improved survival rate of rats
treated with lysis-deficient T4LyD phage was attributed to
lower endotoxin release [16].
We wished to generate an endolysin-deficient phage
against a gram-positive bacterium, and chose S. aureus
because of its clinical relevance. S. aureus is a major patho-
gen responsible for a variety of diseases ranging from
minor skin infections to life-threatening conditions such as
sepsis. This pathogen is often resistant to all b-lactam anti-
biotics; vancomycin-resistant strains may become untrea-
table [17-19]. This organism is the most common cause of
nosocomial infections, and nasal carriage is implicated as a
risk factor [20]. In the United States alone, invasive methi-
cillin-resistant S. aureus (MRSA) infections occur in
approximately 94,000 people each year, causing nearly
19,000 deaths [21]. Understandably, the progressive multi-
drug resistance of bacteria has motivated the re-evaluation
of phages as therapy for diverse bacterial infections [22].
We report here that the recombinant endolysin-deficient
S. aureus phage P954 kills cells without causing cell lysis
and forms plaques on a host that expresses a plasmid-
encoded heterologous endolysin, enabling its large-scale
production. The recombinant phage P954 was evaluated
for in vivo efficacy in an experimental mouse model and
found to protect mice from fatal S. aureus infection.
Methods
Bacterial strains, plasmids, and growth conditions
E. coli strain DH5a [F80dlacZΔM15 Δ (lacZYA-argF)
recA1 endA1 hsdR17 supE44 thi-1 gyrA96relA1deoR] was
used as host for plasmid constructions and plasmid propa-
gation. A restriction-deficient prophage-free S. aureus
strain RN4220 [23] was used for recombination, lysogen-
ization, and phage enrichment. Clinical isolates of S. aur-
eus were used to test phage sensitivity. A MRSA clinical
isolate (B911) was used in animal experiments to deter-
mine the in vivo efficacy of the endolysin-deficient phage
P954.
The plasmid pET21a (Novagen, USA) was used for
cloning and construction of endolysin disruption cassette.
The plasmid pSK236, an E. coli - S. aureus shuttle vector
containing pUC19 cloned into the HindIII site of S. aur-
eus plasmid pC194 [24], was used as a source for the cat
gene. A shuttle vector containing the temperature-sensi-
tive replication origin of S. aureus, pCL52.2, was used as
source for the replication origin [25]. The constitutive
Bacillus subtilis vegII promoter was derived from pRB474
[26]. All bacterial strains were cultured in liquid Luria
Bertani (LB) medium at 37°C on a rotary shaker (200
rpm) unless otherwise stated. Ampicillin, chlorampheni-
col, and tetracycline were used as needed. All chemicals
were obtained from Sigma-Aldrich, St. Louis, MO, USA
unless otherwise mentioned.
Propagation, concentration, and enumeration of
bacteriophages
Bacteriophage P954 is a temperate phage that was isolated
from the Ganges River (India) and amplified in S. aureus
strain RN4220. Briefly, S. aureus RN4220 was grown at 37°
C in LB medium to an absorbance of approximately 0.8 at
600 nm, infected with phage P954 at a multiplicity of infec-
tion (MOI) of 0.01, and cultured at 37°C until the culture
lysed completely. After centrifugation at 4100 × g for 10
min to remove cell debris, the bacteriophages were concen-
trated by centrifugation at 27,760 × g for 90 min. The bac-
teriophage titer was determined by enumerating plaque-
forming units (PFUs) in serial 10-fold dilutions in LB med-
i u ma n dc o n f i r m e db yt h ea g a ro v e r l a ym e t h o d[ 2 7 , 2 8 ] .
Preparation of phage P954 DNA and genome sequencing
Phage P954 DNA was prepared from a stock solution (1 ×
10
12 PFU/ml). The concentrated phage preparation (1 ml)
was incubated at 37°C for 1 hr with DNase I (1 μg/ml) and
RNase A (100 μg/ml). The mixture was adjusted to con-
tain 1% sodium dodecyl sulfate, 50 mM EDTA (pH 8.0),
and 0.5 μg proteinase K and incubated at 65°C for 60 min.
The mixture was then subjected to phenol-chloroform-
isoamyl alcohol (25:24:1) extraction, and the DNA was
precipitated [29]. Purified phage DNA was used for gen-
ome sequencing [GenBank: GQ398772].
Construction of plasmids for phage P954 endolysin
disruption
The phage P954 endolysin gene (753 bp) was amplified as
two separate fragments by polymerase chain reaction
(PCR). The first fragment (bp 1-376) was amplified with
forward primer 5’-CGGAATTCcatatgAAAACATA-
CAGTGAAGCAAGAGCA-3’, containing an NdeI restric-
tion site, and reverse primer 5’-CCGCCGCTgaattcTAAT
AAAGTGAGTACAGCC-3’, containing an EcoRI site.
T h ef r a g m e n tw a sc l o n e di n t oap E T 2 1 av e c t o ra tt h e
NdeI/EcoRI sites.
The second fragment (bp 377-753) was amplified with
forward primer 5’-CCGCCGGgaattcAGTATAAAAGT-
GAGGGCTTA-3’, containing an EcoRI site, and reverse
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CAATCTCTC-3’, containing a HindIII site. The second
f r a g m e n tw a sc l o n e di nt a n d e mw i t ht h ef i r s tf r a g m e n t ,
thus generating the full-length phage P954 lysin gene
with an internal EcoRI site. The cat gene was isolated
along with its constitutive promoter from the S. aureus
- E. coli shuttle plasmid pSK236 by ClaI digestion.
Cohesive ends were filled with the Klenow fragment of
DNA polymerase I and ligated into the blunted EcoRI
site of the full-length phage P954 endolysin gene,
thereby disrupting it. The S. aureus-specific tempera-
ture-sensitive origin of replication from the shuttle vec-
tor pCL52.2 was introduced at the XhoI restriction site
of this construct to generate pGMB390.
Mitomycin C induction of phage P954 lysogens
The S. aureus RN4220 lysogen of phage P954 was inocu-
lated in LB medium and incubated at 37°C with shaking
at 200 rpm for 16 hr. The cells were then subcultured in
LB medium at 2% inoculum and incubated at 37°C with
shaking at 200 rpm until the culture attained an absor-
bance of 1.0 at 600 nm. Mitomycin C was then added to
a final concentration of 1 μg/ml, and the culture was
incubated at 37°C with shaking at 200 rpm for 4 hr for
prophage induction.
Recombination and screening for recombinants
S. aureus RN4220 cells were transformed with pGMB390
by electroporation according to the protocol described by
Schenk and Laddaga [30] with a BioRad Gene Pulser, pla-
ted on LB agar containing chloramphenicol (10 μg/ml),
and incubated at 37°C for 16 hr. Chloramphenicol-resis-
tant colonies were selected and grown in LB at 37°C until
the cultures reached an absorbance of 1.0 at 600 nm.
Recombination was then initiated by infecting these cells
with phage P954 (MOI = 3) for 30 min. Progeny phage
were harvested from the lysate as described previously,
lysogenized in S. aureus RN4220, and plated on LB agar
containing chloramphenicol (10 μg/ml) (round I).
Ninety-six chloramphenicol-resistant colonies were
picked up, grown, and induced with Mitomycin C. Cul-
tures that did not lyse after the 16-hr Mitomycin C
induction were treated with 1% chloroform and lysed
with glass beads; the released phages were again lysogen-
ized in S. aureus RN4220 (round II). Chloramphenicol-
resistant colonies of round II lysogens were similarly
grown and subjected to Mitomycin C induction. The
chloramphenicol-resistant lysogens that did not release
phages upon Mitomycin C induction were selected for
PCR analysis. Genomic DNA of the selected lysogens was
purified, and PCR was performed with different sets of
primers to confirm disruption of the phage P954 endoly-
sin gene.
Endolysin complementation for phage enrichment and
enumeration
The endolysin gene from a Podoviridae phage in our col-
lection, P926, was cloned under the constitutive B. subtilis
vegII promoter in an E. coli - S. aureus shuttle vector con-
structed in our laboratory. This construct, designated
pGMB540, was used for trans-complementation of the
nonfunctional endolysin for propagation of the recombi-
nant phage in lytic mode and for their enumeration. Plas-
mid pGMB540 was introduced into S. aureus strain
RN4220 by electroporation according to the protocol
described by Schenk and Laddaga [30]. Transformants
were selected on LB medium containing tetracycline
(5 μg/ml) and used as bacterial hosts for phage enrich-
ment. Early log phase cells of S. aureus RN4220/
pGMB540 grown at 37°C were infected with the recombi-
nant endolysin-deficient phage P954 (MOI = 0.1) and
incubated for an additional 3 to 4 hr until the culture
lysed. The phage-containing lysate was passed through a
0.2-μm filter, and the phages were enumerated on a lawn
of S. aureus RN4220/pGMB540 cells.
The endolysin-deficient phage P954 was also enriched
by induction. Briefly, the lysogen was grown at 37°C until
absorbance at 600 nm reached 1.0 and then induced with
1 μg/ml Mitomycin C at 37°C for 4 hr. The cells were pel-
leted and lysed by vortexing with glass beads. Cell debris
was removed by centrifugation at 5000 × g for 10 min,
and the phage-containing supernatant was passed through
a 0.2-μm filter.
Comparison of in vitro bactericidal activity of parent and
lysis-deficient phage P954
The parent and recombinant phages were compared for
host range and bactericidal activity. Ten MOI equivalent
of phage was added to 2 × 10
8 colony-forming units per
ml (CFU/ml) and incubated at 37°C for 90 min. Serial
10-fold dilutions of the mixture were plated on LB agar,
and residual viable cells (CFUs) were enumerated.
In vivo efficacy of endolysin-deficient phage P954 in
neutropenic mice
Animal experiments were performed at St. John’s Medical
College and Hospital, Bangalore, India. The experiments
were approved by the Institutional Animal Ethics Com-
mittee and the Committee for the Purpose of Control and
Supervision of Experiments on Animals (registration No.
90/1999/CPCSEA dated 28/4/1999).
Healthy male Swiss albino mice (6-8 weeks old, neutro-
penic) were used to evaluate in vivo efficacy. Neutropenia
was induced by intraperitoneal (IP) administration of
cyclophosphamide (100 mg/kg). In a preliminary study,
the lethality of a clinical MRSA isolate (B911) was deter-
mined in the mice (1 × 10
7 -1 × 10
8 CFU). We found
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7 CFU resulted in 80% mortality (LD80), and it
was therefore chosen as the challenge dose to evaluate
phage efficacy (data not shown).
In the efficacy experiment, mice were assigned to six
treatment groups (n = 8, each group). Four days after
cyclophosphamide treatment, the mice in groups 1-3
were challenged with B911 (200 μl, 5 × 10
7 CFU).
G r o u p s1a n d4w e r et h e nt r e a t e dw i t h2 5m MT r i s -
HCl, pH 7.5 (negative control); groups 2 and 5 were
treated with two doses of endolysin-deficient phage
P954 prepared in 25 mM Tris-HCl, pH 7.5 at 200 MOI
equivalent (MOI relative to CFU at LD80); and groups 3
and 6 were treated with two doses of chloramphenicol
(50 mg/kg). The first treatment dose was administered
immediately after challenge; the second dose was admi-
nistered 2 hr later. Mice were observed over 10 days for
occurrence of mortality. Survival analysis is plotted as
Kaplan-Meier survival curves using MedCalc statistical
software version 11.6.0.0 (Mariakerke, Belgium).
Results
Genome of phage P954
The 40761-bp phage P954 genome (Genome map pro-
vided as Additional file 1 Figure S1) is composed of linear
double-stranded DNA with a G+C content of 33.99%
[GenBank: GQ398772]. BlastN [31] searches with the
phage P954 nucleotide sequence showed it to be similar to
other sequenced staphylococcal phages in the NCBI data-
base. The P954 genome matches that of S. aureus phage
phiNM3 (accession no. DQ530361) with pair-wise identity
of 66%. At least 69 open reading frames (ORFs) were pre-
dicted with the GeneMark program [32]. Bioinformatics
analysis revealed that 46 of the 69 ORFs are hypothetical/
conserved hypothetical proteins; the other 23 ORFs show
a high degree of homology to proteins from other staphy-
lococcal phages in the database. The lysis cassette of this
phage was found to be similar to lysis systems of other
staphylococcal phages. The closest match to the phage
P954 holin gene was staphylococcal prophage phiPV8,
with 97% identity. The endolysin gene of phage P954 is
100% identical to the amidase gene from staphylococcal
phage phi13; the phage P954 integrase gene is 100% iden-
tical to ORF 007 of staphylococcal phage 85; and the
phage P954 repressor gene is 100% identical to the puta-
tive phage repressor of S. aureus subsp JH9. Our analysis
did not reveal the presence of any toxin encoding genes in
the phage P954 genome.
Screening of recombinants
The native phage endolysin gene was inactivated, and the
recombinant phage engendered by homologous recombi-
nation between phage P954 and plasmid pGMB390 in
S. aureus RN4220. Screening for S. aureus RN4220 lyso-
gens harboring recombinant phage P954, in which
endolysin was inactivated by insertion of the cat gene, was
carried out using chloramphenicol resistance as a marker.
Ninety-six colonies were obtained of which two lysogens
did not show lysis with Mitomycin C induction for up
to 16 hours. Phages mechanically released from these
colonies upon relysogenization yielded chloramphenicol
r e s i s t a n tl y s o g e n st h a td i dn o tl y s eu p o nM i t o m y c i nC
induction. PCR analyses using two primer sets confirmed
disruption of the endolysin gene in all the recombinant
lysogens screened. Representative PCR profile of recombi-
nant and parent phage lysogens is shown (Figure 1).
Mitomycin C induction of parent and endolysin-deficient
phage P954
We examined the prophage induction pattern and phage
progeny release from parent and endolysin-deficient phage
P954 lysogens. Absorbance and extracellular phage titers
were monitored every hour until the end of induction.
Induction of the parent phage P954 lysogen (B7) resulted
in cell lysis and gave a phage titer of 1 × 10
9 PFU/ml. In
contrast, the endolysin-deficient phage P954 lysogen did
not lyse and gave a phage titer of about 10
3 PFU/ml
(Figure 2).
Endolysin complementation for phage enrichment and
enumeration
Endolysin-deficient phage P954 could be enriched to
titers of up to 5 × 10
10 PFU/ml in S. aureus RN4220
that constitutively expressed phage P926 endolysin. This
strain was used also to determine titers of the endoly-
sin-deficient phage preparations. When preparations of
the endolysin-deficient phage were spotted on a non-
complementing host, a zone of lysis characteristic of
“lysis from without” was observed at lower dilutions,
and no plaques were discernible (Figure 3a). The recom-
binant phage formed plaques only on the endolysin-
complementing host (Figure 3b, c, d).
Comparison of in vitro bactericidal activity of parent and
lysis-deficient phage P954
Parent and recombinant endolysin-deficient phage P954
demonstrated comparable bactericidal activity when
tested on a panel of seven phage-sensitive and one
phage-resistant (B9030) clinical isolates, comprising
both methicillin-sensitive S. aureus (MSSA) and MRSA
strains, from our collection. Cell viability was reduced
by ≥ 90% with both phages (Figure 4). Similarly, the
host range of each phage was the same on a panel of 20
phage-sensitive and phage-resistant clinical isolates (data
provided as Additional file 2 Table S1).
In vivo efficacy of endolysin-deficient phage P954
An IP injection of the MRSA isolate B911 (5 × 10
7 cells/
mouse) resulted in the onset of disease in 80% of mice
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within 48 hr (Figure 5). However, IP administration of
endolysin-deficient phage P954 as two doses (immedi-
ately and after 2 hr) post B911 challenge fully protected
the mice against lethality (group 2). Similarly, chloram-
phenicol (dose regimen similar to phage) protected mice
against lethality (group 3); however, one animal died in
each of the chloramphenicol treatment groups of
unknown causes (groups 3 and 6). Endolysin-deficient
phage alone was not toxic or lethal to neutropenic mice,
demonstrating its safety (group 5). Endolysin-deficient
phage demonstrated significant efficacy against MRSA
B911in the tested animal model (P value = 0.0001).
Discussion
Bacteriophage endolysins are peptidoglycan hydrolases
that function at the end of the phage multiplication cycle,
lysing the bacterial cell and releasing new phages to
infect other bacteria. Many efforts to develop therapeutic
phages have focused on the lytic endpoint of phage infec-
tion to destroy the bacterium. However, cell lysis by
phage may present the problem of endotoxin release and
serious consequences as known in the case of antibiotics
[33]. Antibiotic-induced release of Lipotiechoic acids and
peptidoglycan (PG) in case of gram positive bacteria has
been shown to enhance systemic inflammatory responses
[34]. An endolysin-deficient phage does not degrade the
bacterial cell wall, thus progeny are not released until the
cell disintegrates or is lysed by other means. However,
the phage protein holin, produces an inner membrane
lesion at the end of the phage replication cycle, which
terminates respiration [7] and ensures killing of the cell.
In an in vivo situation, we can expect such dead cells to
be cleared rapidly by the host immune system.
Non-replicating genetically modified filamentous
phage which exerted high killing efficiency on cells with
minimal release of endotoxin is reported [13]. Higher
survival rate correlated with reduced inflammatory
response in case of infected mice treated with geneti-
cally modified phage [14]. A phage genetically engi-
neered to produce an enzyme that degrades extracellular
polymeric substances and disperses biofilms is reported
[15].
Although temperate phages present the problem of lyso-
geny and the associated risk of transfer of virulence factors
through bacterial DNA transduction; we have used a tem-
perate phage as a model for this study as the prophage sta-
tus simplifies genetic manipulation. Because S. aureus
strains are known to harbor multiple prophages, which
could potentially interfere with recombination and engi-
neering events, we elected to lysogenize phage P954 in a
prophage-free host, S. aureus RN4220. Our strategy was to
identify lysogens that harbored the recombinant endoly-
sin-deficient phages, based on detection of phage P954
genes and the cat marker gene by PCR analysis (Figure 1).
In the recombination experiment, the 96 chloramphe-
nicol resistant colonies obtained represented recombi-
nant endolysin-inactivated prophage some of which lysed
upon Mitomycin C induction. We suspected that the par-
ent phage could also have lysogenized along with the
a 
b
c  d
Figure 1 Schematic and PCR analysis of parent and recombinant endolysin-deficient phage P954. Alignment of primers to the (a) parent
phage DNA template and (b) recombinant phage DNA template, in which the cat gene had been inserted into the endolysin gene (LYS). (c)
Endolysin forward and reverse primers yield a 750-bp PCR product of the parent phage P954 and 2400-bp product of the recombinant phage
P954. (d) The holin forward primer and endolysin reverse primer yield a 1000-bp PCR product with parent phage P954 and 2650-bp product of
the recombinant phage P954. Both PCR panels include lane 1: PCR buffer (negative control); lane 2: parent phage P954 lysogen B7, lane 3:
molecular weight marker (l/HindIII-EcoRI); lane 4: recombinant phage P954 lysogen H10.
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repeating the induction of chloramphenicol resistant
lysogens and lysogenization of the phages produced.
When we assessed the prophage induction pattern and
phage progeny release of parent and endolysin-deficient
phage P954 lysogens, we found that the absorbance of
the culture remained unaltered and the extracellular
phage titer was minimal with the recombinant phage
lysogen. We observed a low phage titer 3 to 4 hours
after induction, presumably due to natural disintegration
Figure 2 Mitomycin C induction of parent and endolysin-deficient phage P954 lysogens. (a) Growth profiles of the parent (B7) and
endolysin-deficient (H10) phage P954 lysogens after Mitomycin C induction showing absorbance of cultures at 600 nm. The graph is
representative of two experiments. The error bars represent mean plus standard deviation (n = 3) (b) Phage release into the culture medium
from parent (B7) and endolysin-deficient (H10) phage P954 lysogens after Mitomycin C induction. The graph is representative of 2 experiments.
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contrast, we observed lysis of the culture by the parent
phage with increasing phage titer in the lysate, as
expected (Figure 2).
Complementation of the lysis-deficient phenotype was
achieved using a heterologous phage P926 from our col-
lection. Supplying the endolysin gene in trans allowed the
recombinant phage to form plaques (Figure 3b, d). This
Figure 3 Complementation with heterologous endolysin gene for enrichment of endolysin-deficient phage P954. Ten-fold serial
dilutions of endolysin-deficient phage P954 (5 × 10
10 PFU/ml) spotted on (a) S. aureus RN4220 lawn and (b) complementing host pGMB540/S.
aureus RN4220, which expresses a heterologous endolysin. Plaque assay of enriched endolysin-deficient phage P954 on (c) non-complementing
host S. aureus RN4220 and (d) complementing host pGMB540/S. aureus RN4220.
Figure 4 Bactericidal activity of parent and lysis-deficient phage P954. Bactericidal activity of parent and lysis-deficient phage P954 (10 MOI
equivalent) on eight clinical isolates of MRSA (B910, B954, B9053, B9194, B9195) and MSSA (B911, B9007, B9030). Phage resistant isolate indicated
with asterix (*). The error bars represent standard deviation (n = 3, single experiment).
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phage throughout our study, and provided an excellent
method for efficient phage enrichment. Use of a heterolo-
gous phage endolysin enabled the recombinant phage to
exhibit the lysis-deficient phenotype even after several
rounds of multiplication. In vitro activity of the endolysin-
deficient phage against MSSA and MRSA was comparable
to that of the parent phage (Figure 4). Further, the recom-
binant phage was able to rescue mice from fatal MRSA
infection (Figure 5), similar to the parent phage (data not
shown). Future studies will have to compare systemic
responses and outcomes of treatment with native and
endolysin- deficient phage in S. aureus infection.
This work demonstrates the potential of disrupting the
endolysin gene to reduce the number of phages that are
otherwise released post-infection by their lytic parent
phage. In clinical situations, this would provide the
advantage of a defined dosage, which is an important
concern raised against phage therapy [5,35], as well as
lower immune response and reduced endotoxin release
when using gram-negative bacteria. This is the first
report of a gram-positive endolysin-deficient phage. Our
results demonstrate the therapeutic potential of engi-
neered phages in clinical applications.
Conclusions
We developed a modified bacteriophage against S. aur-
eus by insertional inactivation of its endolysin gene,
which renders it incapable of host cell lysis. This phage
is lethal to cells it infects, with little or no release of
progeny phage. We showed that the disrupted endolysin
could be complemented with a functional heterologous
endolysin gene to produce this phage in high titers. To
our knowledge, this is the first report of a gram-positive
endolysin-deficient phage. Further, we demonstrate its
therapeutic potential in an experimental infection model
in mice, in which the lysis-deficient phage P954 protects
against lethal MRSA.
Additional material
Additional file 1: Figure S1 - Genome map of phage P954. Phage
P954 genome is similar in organization to other known temperate
staphylococcal phages. The organization of the genome is modular, with
genes involved in lysogeny, replication, DNA packaging, tail assembly,
and lysis arranged sequentially).
Additional file 2: Table S1 - Comparison of host range of parent
and endolysin deficient phage P954. The host range of both the
phage were same on a panel of 20 phage-sensitive and phage-resistant
isolates.
Figure 5 In vivo efficacy of endolysin-deficient phage P954. Survival of mice challenged with clinical MRSA isolate (B911). Groups 1-3 were
challenged with MRSA (5 × 10
7 cells per mouse). Groups 4-6 were not challenged with MRSA and served as controls. The following treatments
were administered: groups 1 and 4 (25 mM Tris-HCl, pH 7.5); groups 2 and 5 (two doses of endolysin-deficient phage P954, 200 MOI); groups 3
and 6 (two doses of chloramphenicol, 50 mg/kg).
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cat: Chloramphenicol acetyltransferase; CFU: Colony-forming unit; IP:
Intraperitoneal; LB: Luria Bertani; LD80: Lethal dose that results in 80% mortality;
MOI: Multiplicity of infection; MRSA: Methicillin-resistant Staphylococcus aureus;
MSSA: Methicillin-sensitive Staphylococcus aureus; PFU: Plaque-forming unit
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